- Home
- SUPN vs RPD Comparison
SUPN vs RPD Comparison
Compare SUPN & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- RPD
- Stock Information
- Founded
- SUPN 2005
- RPD 2000
- Country
- SUPN United States
- RPD United States
- Employees
- SUPN N/A
- RPD N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- RPD Computer Software: Prepackaged Software
- Sector
- SUPN Health Care
- RPD Technology
- Exchange
- SUPN Nasdaq
- RPD Nasdaq
- Market Cap
- SUPN 2.1B
- RPD 2.5B
- IPO Year
- SUPN 2012
- RPD 2015
- Fundamental
- Price
- SUPN $33.05
- RPD $31.71
- Analyst Decision
- SUPN Hold
- RPD Buy
- Analyst Count
- SUPN 2
- RPD 20
- Target Price
- SUPN $36.00
- RPD $41.94
- AVG Volume (30 Days)
- SUPN 464.2K
- RPD 801.7K
- Earning Date
- SUPN 02-25-2025
- RPD 02-12-2025
- Dividend Yield
- SUPN N/A
- RPD N/A
- EPS Growth
- SUPN 130.79
- RPD N/A
- EPS
- SUPN 1.07
- RPD 0.40
- Revenue
- SUPN $651,972,000.00
- RPD $844,007,000.00
- Revenue This Year
- SUPN $7.94
- RPD $5.90
- Revenue Next Year
- SUPN N/A
- RPD $6.52
- P/E Ratio
- SUPN $31.70
- RPD $79.05
- Revenue Growth
- SUPN 6.79
- RPD 8.53
- 52 Week Low
- SUPN $25.53
- RPD $31.52
- 52 Week High
- SUPN $40.28
- RPD $59.43
- Technical
- Relative Strength Index (RSI)
- SUPN 32.98
- RPD 19.89
- Support Level
- SUPN $32.53
- RPD $33.70
- Resistance Level
- SUPN $39.99
- RPD $38.98
- Average True Range (ATR)
- SUPN 1.31
- RPD 1.36
- MACD
- SUPN -0.69
- RPD -0.61
- Stochastic Oscillator
- SUPN 6.71
- RPD 2.41
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.